Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Wednesday.

Several other research analysts also recently commented on CRME. ValuEngine raised shares of Cardiome Pharma Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Zacks Investment Research downgraded shares of Cardiome Pharma Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Canaccord Genuity set a $8.00 price target on shares of Cardiome Pharma Corporation and gave the company a “buy” rating in a report on Monday, August 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Cardiome Pharma Corporation currently has an average rating of “Hold” and an average target price of $5.44.

Cardiome Pharma Corporation (NASDAQ:CRME) opened at $1.52 on Wednesday. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. Cardiome Pharma Corporation has a 1 year low of $1.29 and a 1 year high of $4.84.

Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) last issued its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The business had revenue of $6.02 million for the quarter, compared to the consensus estimate of $7.42 million. Cardiome Pharma Corporation had a negative return on equity of 94.68% and a negative net margin of 112.91%. Cardiome Pharma Corporation’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) EPS. research analysts forecast that Cardiome Pharma Corporation will post -0.82 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/22/cardiome-pharma-corporation-crme-stock-rating-reaffirmed-by-hc-wainwright.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its holdings in Cardiome Pharma Corporation by 5.0% in the first quarter. Renaissance Technologies LLC now owns 65,313 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 3,100 shares during the period. Turner Investments L.P. boosted its stake in shares of Cardiome Pharma Corporation by 2.3% in the fourth quarter. Turner Investments L.P. now owns 708,888 shares of the biopharmaceutical company’s stock worth $5,749,000 after acquiring an additional 15,766 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Cardiome Pharma Corporation by 49.0% in the third quarter. PNC Financial Services Group Inc. now owns 53,000 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 17,420 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in shares of Cardiome Pharma Corporation in the second quarter worth approximately $109,000. Finally, JPMorgan Chase & Co. boosted its stake in Cardiome Pharma Corporation by 37.6% during the second quarter. JPMorgan Chase & Co. now owns 155,095 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 42,416 shares during the last quarter. Institutional investors and hedge funds own 55.12% of the company’s stock.

About Cardiome Pharma Corporation

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.